المؤلفون: Ondrej Viklicky, Jelena Skibova, Eva Honsova, Janka Slatinska, I. Striz, Jitka Brozova, Zuzana Sekerkova, Antonij Slavcev

المصدر: Archivum Immunologiae et Therapiae Experimentalis. 64:47-53

مصطلحات موضوعية: Adult, Graft Rejection, Male, Risk, 0301 basic medicine, Time Factors, medicine.medical_treatment, Immunology, Human leukocyte antigen, 030230 surgery, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, HLA Antigens, Isoantibodies, B-Cell Activating Factor, medicine, Humans, Immunology and Allergy, Renal Insufficiency, B-cell activating factor, Kidney transplantation, Aged, Aged, 80 and over, B-Lymphocytes, Kidney, biology, business.industry, General Medicine, Middle Aged, medicine.disease, Kidney Transplantation, Tissue Donors, Transplantation, 030104 developmental biology, medicine.anatomical_structure, Cytokine, Antibody mediated rejection, biology.protein, Female, Antibody, business

الوصف: The B-cell activating factor (BAFF) cytokine has important functions for the survival and maturation of B lymphocytes, which implies that this cytokine might play a role in the development of antibody-mediated rejection (AMR) after kidney transplantation. In our study, we compared the concentrations of the soluble BAFF cytokine in kidney graft recipients with AMR and patients without rejection with the goal of testing the hypothesis whether BAFF level measurement might be useful as a diagnostic marker of AMR. The study included a cohort of 19 high-risk patients with diagnosed AMR and 17 control patients free of rejection. BAFF was measured in all patients before transplantation, during the rejection episodes, and three months after transplantation in patients free of rejection using the Luminex technique. Before transplantation, the serum concentrations of BAFF in patients with AMR and kidney recipients without rejection did not significantly differ. After transplantation, however, BAFF levels were significantly lower in patients with AMR and also in patients with concurrent humoral and cellular rejection compared with patients without rejection (p

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc75c2778b48406182e3cf00c952bfb5Test
https://doi.org/10.1007/s00005-016-0428-4Test

المؤلفون: Marcela Bürgelova, I. Striz, Yelena Pavlova, Janka Slatinska, Jelena Skibova, L. Kolesar, Ondrej Viklicky, Eva Honsova, Antonij Slavcev, Caner Süsal

المصدر: Transplant Immunology. 25:72-76

مصطلحات موضوعية: Graft Rejection, Male, medicine.medical_specialty, Time Factors, medicine.medical_treatment, Immunology, Ki-1 Antigen, Gastroenterology, Isoantibodies, HLA Antigens, Internal medicine, medicine, Humans, Transplantation, Homologous, Immunology and Allergy, Survival rate, Kidney transplantation, Aged, Retrospective Studies, Transplantation, Kidney, biology, Hepatocyte Growth Factor, business.industry, Middle Aged, medicine.disease, Kidney Transplantation, Survival Rate, Cytokine, medicine.anatomical_structure, Antibody Formation, biology.protein, Female, Hepatocyte growth factor, Antibody, business, Biomarkers, medicine.drug

الوصف: Our retrospective study was aimed to assess the relevance of pre- and post-transplant measurements of serum concentrations of the soluble CD30 molecule (soluble CD30, sCD30) and the cytokine Hepatocyte growth factor (HGF) for prediction of the risk for development of antibody-mediated rejection (AMR) in kidney transplant patients. Evaluation of sCD30, HGF levels and the presence of HLA-specific antibodies in a cohort of 205 patients was performed before, 2weeks and 6months after transplantation. Patients were followed up for kidney graft function and survival for two years. We found a tendency of higher incidence of AMR in retransplanted patients with elevated pre-transplant sCD30 (≥100U/ml) (p=0.051), however no such correlation was observed in first-transplant patients. Kidney recipients with simultaneously high sCD30 and HLA-specific antibodies (sCD30+/Ab+) before transplantation had significantly lower AMR-free survival compared to the other patient groups (p0.001). HGF concentrations were not associated with the incidence of AMR at any time point of measurement, nevertheless, the combined analysis HGF and sCD30 showed increased incidence of AMR in recipients with elevated pretransplant sCD30 and low HGF levels.the predictive value of pretransplant sCD30 for the development of antibody-mediated rejection after transplantation is significantly potentiated by the co-presence of HLA specific antibodies. The role of HGF as a rejection-protective factor in patients with high pretransplant HGF levels would need further investigation.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eb3ed66e98ca9674465100011b1ca58Test
https://doi.org/10.1016/j.trim.2011.02.003Test

المؤلفون: Yelena Pavlova, Ivan Málek, Ivan Netuka, Eva Honsova, I. Striz, Jelena Skibova, A. Lodererova, L. Kolesar, J. Sochman, Antonij Slavcev

المصدر: ResearcherID

مصطلحات موضوعية: Adult, Graft Rejection, Male, medicine.medical_specialty, medicine.medical_treatment, Immunology, Human leukocyte antigen, Biochemistry, Organ transplantation, Antigen, HLA Antigens, Isoantibodies, Predictive Value of Tests, MHC class I, Genetics, medicine, Humans, Immunology and Allergy, Retrospective Studies, Heart transplantation, biology, Hepatocyte Growth Factor, business.industry, Histocompatibility Antigens Class I, General Medicine, Middle Aged, Transplantation, Cytokine, Acute Disease, biology.protein, Heart Transplantation, Female, Antibody, business, Biomarkers

الوصف: Recent unconfirmed literature data suggest that elevated concentrations of the multifunctional cytokine hepatocyte growth factor (HGF) might be a marker of increased incidence of acute rejection after organ transplantation. The aim of this study was to test the hypothesis that HGF levels may correlate with the rejection and/or with the production of HLA and MHC Class I chain-related antigens A (MICA) specific antibodies. Sixty-three heart transplant recipients were included into the study. Hundred and eighty-five endomyocardial biopsies (EMB) obtained up to 6 months after transplantation were retrospectively analyzed for signs of cellular (CR) and antibody-mediated rejection (AMR). Pre- and post-transplant sera were tested for HGF concentrations and antibodies to HLA class I, class II and MICA antigens by xMap technology (Luminex). Pre-transplant HGF did not correlate with the incidence of CR or AMR. However, higher HGF concentrations correlated significantly with HLA antibody production before and after transplantation (P = 0.006 and P < 0.0001 respectively). Patients with both HLA class I and class II antibodies before transplantation had significantly lower AMR-free survival. Furthermore, recipients with pre-transplant donor-specific antibodies (DSA) had significantly lower AMR-free survival (50%) than recipients without pre-transplant HLA antibodies (90%) and patients with antibodies not specific to donor antigens (92%) (P = 0.005). Post-transplant MICA antibodies tended to be more frequent in patients with AMR (P = 0.063). In conclusion, elevated HGF concentrations in our study were not associated with the incidence of CR and/or AMR but with the presence of HLA-specific antibodies. Testing for DSA before heart transplantation by Luminex may be helpful for the identification of patients with increased risk of AMR.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d721f2b06757e344b8482924b4afd3fTest
https://doi.org/10.1111/j.1399-0039.2010.01523.xTest

المؤلفون: Jan Maly, A. Lodererova, Marcela Bürgelova, Eva Novotna, Miroslav Merta, Irena Brabcova, Vladimir Tesar, Jelena Skibova, Ondrej Viklicky, Eva Honsova, Josef Zadrazil, Petra Hribova, Dita Maixnerova

المصدر: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 26(2)

مصطلحات موضوعية: Adult, Male, Chemokine, Pathology, medicine.medical_specialty, medicine.medical_treatment, Biopsy, Gene Expression, urologic and male genital diseases, Kidney, Nephropathy, Transforming Growth Factor beta1, medicine, Humans, Prospective Studies, Vascular Diseases, Transplantation, biology, medicine.diagnostic_test, business.industry, Glomerulosclerosis, Glomerulonephritis, Glomerulonephritis, IGA, Middle Aged, medicine.disease, Prognosis, Cytokine, Cross-Sectional Studies, Nephrology, Immunology, biology.protein, Disease Progression, Hepatocyte growth factor, Female, business, medicine.drug, Transforming growth factor, Follow-Up Studies

الوصف: Background The mechanism of IgA nephropathy (IgAN) progression remains ill-defined. In this prospective study, the prognostic role of clinical, histological and molecular markers over a 2-year follow-up was evaluated. Methods Fifty-one patients with biopsy-proven IgAN were followed for 24 months. Besides routine histology, the intrarenal gene expressions of cytokines and chemokines were quantified by reverse transcription quantitative real-time polymerase chain reaction, and the presence of lymphocytes and macrophages were immunohistochemically examined. Results Higher transforming growth factor-β1 and severe chronic vasculopathy (but not glomerulosclerosis, interstitial fibrosis or lymphocyte infiltrate) were associated with the IgAN progression 24 months after biopsy. The gene expression of chemokine (C-C motif) ligands 2 and 5, hepatocyte growth factor, bone morphogenic protein-7 and transforming growth factor-β1 and the interstitial infiltrate of T and B lymphocytes and macrophages were significantly associated with serum creatinine and glomerular filtration rate at the time of biopsy. The intrarenal chemokine (C-C motif) ligand 2 and hepatocyte growth factor gene expression were associated with the proteinuria. Conclusions Besides the known risk factors for chronic kidney disease, advanced vasculopathy and molecular signatures of fibrogenesis were associated with the IgAN progression.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::904bd6aa07481614c5ed97cf1d3003d4Test
https://pubmed.ncbi.nlm.nih.gov/20650904Test